These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21633647)

  • 21. Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study.
    Lee S; Yoon SH; Park JY; Kim DY; Ahn SH; Han KH; Choi HJ
    Invest New Drugs; 2012 Jun; 30(3):1150-7. PubMed ID: 21249514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sorafenib, a systemic therapy for hepatocellular carcinoma.
    Méndez-Sánchez N; Vásquez-Fernández F; Zamora-Valdés D; Uribe M
    Ann Hepatol; 2008; 7(1):46-51. PubMed ID: 18376365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete response for advanced liver cancer during sorafenib therapy: case report.
    Sacco R; Bargellini I; Gianluigi G; Bertini M; Bozzi E; Altomare E; Battaglia V; Romano A; Bertoni M; Capria A; Bresci G; Bartolozzi C
    BMC Gastroenterol; 2011 Jan; 11():4. PubMed ID: 21241463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.
    Horger M; Lauer UM; Schraml C; Berg CP; Koppenhöfer U; Claussen CD; Gregor M; Bitzer M
    BMC Cancer; 2009 Jun; 9():208. PubMed ID: 19558720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC).
    Wong H; Tang YF; Yao TJ; Chiu J; Leung R; Chan P; Cheung TT; Chan AC; Pang RW; Poon R; Fan ST; Yau T
    Oncologist; 2011; 16(12):1721-8. PubMed ID: 22135121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hepatocellular carcinoma].
    Yamashita T; Arai K; Kaneko S
    Nihon Rinsho; 2010 Oct; 68(10):1861-5. PubMed ID: 20954330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sorafenib for HCC: a pragmatic perspective.
    Razumilava N; Gores GJ
    Oncology (Williston Park); 2011 Mar; 25(3):300, 302. PubMed ID: 21548475
    [No Abstract]   [Full Text] [Related]  

  • 28. [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
    Amano R; Yamada N; Noda E; Kubo N; Tanaka H; Muguruma K; Takashima T; Yashiro M; Maeda K; Onoda N; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2676-8. PubMed ID: 21224677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
    Li Y; Huang JW; Lu LG; Shao PJ; Hu BS; Huang GM; Wei ZG; Zhang L
    Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(31):2187-92. PubMed ID: 21029658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
    Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
    BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.
    Atkin C; Earwaker P; Pallan A; Shetty S; Punia P; Ma YT
    BMC Gastroenterol; 2017 Feb; 17(1):30. PubMed ID: 28193171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study.
    Teng CL; Hwang WL; Chen YJ; Chang KH; Cheng SB
    World J Surg Oncol; 2012 Feb; 10():41. PubMed ID: 22339891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma.
    Balsom SM; Li X; Trolli E; Rose J; Bloomston M; Patel T; Bekaii-Saab TS
    Oncology; 2010; 78(3-4):210-2. PubMed ID: 20424492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
    Burak KW
    Oncology (Williston Park); 2011 Mar; 25(3):296, 298, 300. PubMed ID: 21548474
    [No Abstract]   [Full Text] [Related]  

  • 35. Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma.
    Horgan AM; Dawson LA; Swaminath A; Knox JJ
    J Gastrointest Cancer; 2012 Jun; 43(2):344-8. PubMed ID: 20683678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The possible role of sorafenib as a part of the multimodal treatment for hepatocellular carcinoma].
    Ishiko T; Beppu T; Chikamoto A; Tanaka H; Masuda T; Okabe H; Mima K; Horino K; Takamori H; Nakahara O; Baba H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2499-501. PubMed ID: 22202426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
    Greten TF; Manns MP; Malek N
    Z Gastroenterol; 2009 Jan; 47(1):55-60. PubMed ID: 19156592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of hepatocellular carcinoma: beyond sorafenib.
    Chan SL; Mok T; Ma BB
    Curr Oncol Rep; 2012 Jun; 14(3):257-66. PubMed ID: 22434314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.
    Kim R; Menon N; Aucejo F
    Med Oncol; 2011 Dec; 28(4):1044-7. PubMed ID: 20635167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.